STIMUFEND®(pegfilgrastim-fpgk)is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
This 20-page guide from Fresenius Kabi covers coding, coverage, billing and reimbursement for STIMUFEND (pegfilgrastim-fpgk), a pegfilgrastim biosimilar. It lists the indication and limitations of use, the recommended dosage and administration, and the codes used on claims: HCPCS Q5127, CPT 96372, ICD-10-CM diagnosis codes, 10- and 11-digit NDC numbers and hospital revenue codes.
The guide also describes the treatment approval and reimbursement process, including benefits verification, prior authorization, copay support through KabiCare, submitting the claim form, payment rates for injectable drugs, submitting for copay assistance, and claim denials and appeals. Important Safety Information is repeated throughout the brochure. The information is stated to be current as of September 2022.
| Recommended dosage (adults) | Single subcutaneous injection of 6 mg once per chemotherapy cycle |
|---|---|
| Administration | Subcutaneous injection via a single-dose, pre-filled syringe for manual use |
| Package and 10-digit NDC | 6-mg/0.6-mL single-dose, pre-filled syringe; 65219-371-10 |
| 11-digit NDC | 65219037110 |
| HCPCS code | Q5127 — Injection, pegfilgrastim-fpgk, biosimilar, (STIMUFEND), 0.5 mg |
| Billable units | 12 billable units for administration of 1 syringe |
| CPT code for injection | 96372 — Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
| Discarded product reporting | Reported on a separate line with Q5127 and the JW modifier |
It is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
It is administered subcutaneously via a single-dose, pre-filled syringe for manual use.
For adult patients with non-myeloid cancer receiving myelosuppressive chemotherapy, the recommended dosage is a single subcutaneous injection of 6 mg once per chemotherapy cycle.
The HCPCS Q-code assigned to STIMUFEND is Q5127, Injection, pegfilgrastim-fpgk, biosimilar, (STIMUFEND), 0.5 mg, effective for dates of service on and after April 1, 2023.